adenoviridae vector ChAdOx1 can be used to make vaccinations that are protective against Middle East Respiratory Syndrome (MERS) in mice and able to...
12 KB (1,137 words) - 22:32, 17 July 2024
respiratory syndrome (MERS) is a viral respiratory infection caused by Middle East respiratory syndrome–related coronavirus (MERS-CoV). Symptoms may range...
87 KB (7,269 words) - 23:58, 31 August 2024
COVID-19 vaccine (category Articles without InChI source)
viral-vectored vaccines: two adenoviral-vectored (ChAdOx1-MERS, BVRS-GamVac) and one MVA-vectored (MVA-MERS-S). Vaccines that use an inactive or weakened...
200 KB (22,796 words) - 05:34, 12 September 2024
the adenoviral vector ChAdOx1 can be used to make vaccinations that are protective against Middle East respiratory syndrome (MERS) in mice and able to...
26 KB (2,719 words) - 22:12, 21 August 2024
as the primary treatment approach. In January 2024 a candidate vaccine, ChAdOx1 NipahB, commenced Phase I clinical trials after completing laboratory and...
24 KB (2,427 words) - 11:54, 19 September 2024
PMID 24530395. Orexin receptor subtypes readily formed homo- and hetero(di)mers, as suggested by significant BRET signals. CB1 receptors formed homodimers...
68 KB (7,780 words) - 04:56, 19 September 2024
production of the ChAdOx1 nCoV-19 vaccination. The team started research in January 2020, and managed to identify a chimpanzee adenovirus vector (ChAdOx) that generated...
13 KB (1,256 words) - 13:22, 12 May 2024
Pfizer–BioNTech COVID-19 vaccine (category Articles without InChI source)
7% against delta, similar to effectiveness provided by one dose of the ChAdOx1 nCoV-19 vaccine. In August 2021, the US Centers for Disease Control and...
260 KB (22,082 words) - 05:55, 13 September 2024
Sputnik V COVID-19 vaccine (category Articles without InChI source)
the Oxford–AstraZeneca COVID‑19 vaccine, uses chimpanzee adenovirus (ChAdOx1) as the vector. For both the Oxford-AstraZeneca COVID-19 and Gam-COVID-Vac...
154 KB (13,880 words) - 03:06, 18 August 2024
distributed 28 days apart. The trials involved participants either receiving the ChAdOx1 nCoV-19 vaccine or a control substance like saline. The efficiency results...
76 KB (9,809 words) - 01:56, 29 June 2024